

In re Application of:
Hall et al.
Application No.: 09/441,966
Filed: November 17, 1999
Page 2

PATENT
Attorney Docket No.: AERO1120-1

IN THE SPECIFICATION

Please amend the specification as set forth below:

Please amend the paragraph beginning on page 10, line 32, and ending on page 11, line 7, as follows:

A significant advantage of the Kunitz domains of the serine protease inhibitor Bikunin and fragments and analogs thereof of the present invention is that they are human proteins, and also less positively charged than Trasylol® (Example 1), thereby reducing the risk of kidney damage on administration of large doses of the proteins. Here and throughout this specification, Trasylol® is the trade name referring to the medicament the active substance of which is aprotinin, which is the bovine serine protease inhibitor of the Kunitz family. The trade name Trasylol® is registered by Bayer Corp. of Leverkusen, Germany. Being of human origin, the protein of the instant invention can thus be administered to human patients with significantly reduced risk of undesired immunological reactions as compared to administration of similar doses of Trasylol®. Furthermore, it was found that bikunin (102-159), bikunin (7-64), and bikunin (1-170) are significantly more potent inhibitors of plasma kallikrein than Trasylol® *in vitro* (Example 3, 4 and 10). Thus bikunin and fragments thereof are expected to be more effective *in vivo* relative to aprotinin.

Please delete the previously filed sequence listing and insert the Substituted Sequence Listing filed herewith.